C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings

Detalhes bibliográficos
Autor(a) principal: Tenforde, Mark W.
Data de Publicação: 2015
Outros Autores: Gupte, Nikhil, Dowdy, David W., Asmuth, David M., Balagopal, Ashwin, Pollard, Richard B., Sugandhavesa, Patcharaphan, Lama, Javier R., Pillay, Sandy, Cardoso, Sandra W., Pawar, Jyoti, Santos, Breno, Riviere, Cynthia, Mwelase, Noluthando, Kanyama, Cecilia, Kumwenda, Johnstone, Hakim, James G., Kumarasamy, Nagalingeswaran, Bollinger, Robert, Semba, Richard D., Campbell, Thomas B., Gupta, Amita, ACTG PEARLS, NWCS 319 Study Group
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/29551
Resumo: Johns Hopkins University School of Medicine. Baltimore, Maryland, United States of America.
id CRUZ_9e5aed6cb9b648b0163506721d3b2e0b
oai_identifier_str oai:www.arca.fiocruz.br:icict/29551
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Tenforde, Mark W.Gupte, NikhilDowdy, David W.Asmuth, David M.Balagopal, AshwinPollard, Richard B.Sugandhavesa, PatcharaphanLama, Javier R.Pillay, SandyCardoso, Sandra W.Pawar, JyotiSantos, BrenoRiviere, CynthiaMwelase, NoluthandoKanyama, CeciliaKumwenda, JohnstoneHakim, James G.Kumarasamy, NagalingeswaranBollinger, RobertSemba, Richard D.Campbell, Thomas B.Gupta, AmitaACTG PEARLSNWCS 319 Study Group2018-10-11T18:58:30Z2018-10-11T18:58:30Z2015TENFORDE, Mark W. et al. C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings. PLoS ONE, v. 10, n. 2, p. 1-16, 2015.1932-6203https://www.arca.fiocruz.br/handle/icict/2955110.1371/journal.pone.0117424engC-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settingsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleJohns Hopkins University School of Medicine. Baltimore, Maryland, United States of America.Johns Hopkins University School of Medicine. Baltimore, Maryland, United States of America.Johns Hopkins University Bloomberg School of Public Health. Baltimore, Maryland, United States of America.University of California Davis Medical Center. Sacramento, California, United States of America.Johns Hopkins University School of Medicine. Baltimore, Maryland, United States of America.University of California Davis Medical Center. Sacramento, California, United States of America.Chiang Mai University. Research Institute for Health Sciences. Chiang Mai, Thailand.Asociación Civil Impacta Salud y Educación (IMPACTA) Peru Clinical Trials Unit. Lima, Peru.University of KwaZulu-Natal. Nelson Mandela School of Medicine. Durban, South Africa.Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.National AIDS Research Institute. Pune, India.Hospital Nossa Senhora da Conceição. Porto Alegre, RS, Brasil.Les Centres Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunites (GHESKIO). Port-Au-Prince, Haiti.University of Witwatersrand. Johannesburg, South Africa.University of North Carolina Project. Kamuzu Central Hospital. Lilongwe, Malawi.Malawi College of Medicine-Johns Hopkins University Research Project. Blantyre, Malawi.University of Zimbabwe. Harare, Zimbabwe.Y.R. Gaitonde Centre for AIDS Research and Education (YRG CARE). Chennai, India.Johns Hopkins University School of Medicine. Baltimore, Maryland, United States of America.Johns Hopkins University School of Medicine. Baltimore, Maryland, United States of America.University of Colorado Denver School of Medicine. Aurora, Colorado, United States of America.Johns Hopkins University School of Medicine. Baltimore, Maryland, United States of America./ Johns Hopkins University Bloomberg School of Public Health. Baltimore, Maryland, United States of America.Objective: The association between pre-antiretroviral (ART) inflammation and immune activation and risk for incident tuberculosis (TB) after ART initiation among adults is uncertain. Design: Nested case-control study (n = 332) within ACTG PEARLS trial of three ART regimens among 1571 HIV-infected, treatment-naïve adults in 9 countries. We compared cases (participants with incident TB diagnosed by 96 weeks) to a random sample of controls (participants who did not develop TB, stratified by country and treatment arm). Methods We measured pre-ART C-reactive protein (CRP), EndoCab IgM, ferritin, interferon gamma (IFN-γ), interleukin 6 (IL-6), interferon gamma-inducible protein 10 (IP-10), lipopolysaccharide (LPS), soluble CD14 (sCD14), tumor necrosis factor alpha (TNF-α), and CD4/DR+/38+ and CD8/DR+/38+ T cells. Markers were defined according to established cutoff definitions when available, 75th percentile of measured values when not, and detectable versus undetectable for LPS. Using logistic regression, we measured associations between biomarkers and incident TB, adjusting for age, sex, study site, treatment arm, baseline CD4 and log10 viral load. We assessed the discriminatory value of biomarkers using receiver operating characteristic (ROC) analysis. Results: Seventy-seven persons (4.9%) developed incident TB during follow-up. Elevated baseline CRP (aOR 3.25, 95% CI: 1.55–6.81) and IP-10 (aOR 1.89, 95% CI: 1.05–3.39), detectable plasma LPS (aOR 2.39, 95% CI: 1.13–5.06), and the established TB risk factors anemia and hypoalbuminemia were independently associated with incident TB. In ROC analysis, CRP, albumin, and LPS improved discrimination only modestly for TB risk when added to baseline routine patient characteristics including CD4 count, body mass index, and prior TB. Conclusion: Incident TB occurs commonly after ART initiation. Although associated with higher postART TB risk, baseline CRP, IP-10, and LPS add limited value to routine patient characteristics in discriminating who develops active TB. Besides determining ideal cutoffs for these biomarkers, additional biomarkers should be sought that predict TB disease in ART initiators.C-Reactive Protein (CRP)TuberculosisInterferon GammaInducible Protein 10 (IP-10)Lipopolysaccharide (LPS)Antiretroviral Therapyinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83099https://www.arca.fiocruz.br/bitstream/icict/29551/1/license.txt586c046dcfeef936e32f0323bb9a47c0MD51ORIGINALC-reactive protein (CRP), interferon gamma-inducible protein_Sandra_Cardoso_etal_INI_Lapclin-AIDS_2015.pdfC-reactive protein (CRP), interferon gamma-inducible protein_Sandra_Cardoso_etal_INI_Lapclin-AIDS_2015.pdfapplication/pdf604088https://www.arca.fiocruz.br/bitstream/icict/29551/2/C-reactive%20protein%20%28CRP%29%2c%20interferon%20gamma-inducible%20protein_Sandra_Cardoso_etal_INI_Lapclin-AIDS_2015.pdf98ebd3421497c5f0195cbe08318816dbMD52TEXTC-reactive protein (CRP), interferon gamma-inducible protein_Sandra_Cardoso_etal_INI_Lapclin-AIDS_2015.pdf.txtC-reactive protein (CRP), interferon gamma-inducible protein_Sandra_Cardoso_etal_INI_Lapclin-AIDS_2015.pdf.txtExtracted texttext/plain60515https://www.arca.fiocruz.br/bitstream/icict/29551/3/C-reactive%20protein%20%28CRP%29%2c%20interferon%20gamma-inducible%20protein_Sandra_Cardoso_etal_INI_Lapclin-AIDS_2015.pdf.txtc500059aa74417573684970472a9fb81MD53icict/295512018-10-12 02:01:24.331oai:www.arca.fiocruz.br:icict/29551Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUw0KDQpGw6FiaW8gTWFycXVlcywgQ1BGOiAxMTMuMTg3Ljg1Ny00MCwgdmluY3VsYWRvIGEgSU5JIC0gSW5zdGl0dXRvIE5hY2lvbmFsIGRlIEluZmVjdG9sb2dpYSBFdmFuZHJvIENoYWdhcwoKQW8gYWNlaXRhciBvcyBURVJNT1MgZSBDT05EScOHw5VFUyBkZXN0YSBDRVNTw4NPLCBvIEFVVE9SIGUvb3UgVElUVUxBUiBkZSBkaXJlaXRvcwphdXRvcmFpcyBzb2JyZSBhIE9CUkEgZGUgcXVlIHRyYXRhIGVzdGUgZG9jdW1lbnRvOgoKKDEpIENFREUgZSBUUkFOU0ZFUkUsIHRvdGFsIGUgZ3JhdHVpdGFtZW50ZSwgw6AgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaLCBlbQpjYXLDoXRlciBwZXJtYW5lbnRlLCBpcnJldm9nw6F2ZWwgZSBOw4NPIEVYQ0xVU0lWTywgdG9kb3Mgb3MgZGlyZWl0b3MgcGF0cmltb25pYWlzIE7Dg08KQ09NRVJDSUFJUyBkZSB1dGlsaXphw6fDo28gZGEgT0JSQSBhcnTDrXN0aWNhIGUvb3UgY2llbnTDrWZpY2EgaW5kaWNhZGEgYWNpbWEsIGluY2x1c2l2ZSBvcyBkaXJlaXRvcwpkZSB2b3ogZSBpbWFnZW0gdmluY3VsYWRvcyDDoCBPQlJBLCBkdXJhbnRlIHRvZG8gbyBwcmF6byBkZSBkdXJhw6fDo28gZG9zIGRpcmVpdG9zIGF1dG9yYWlzLCBlbQpxdWFscXVlciBpZGlvbWEgZSBlbSB0b2RvcyBvcyBwYcOtc2VzOwoKKDIpIEFDRUlUQSBxdWUgYSBjZXNzw6NvIHRvdGFsIG7Do28gZXhjbHVzaXZhLCBwZXJtYW5lbnRlIGUgaXJyZXZvZ8OhdmVsIGRvcyBkaXJlaXRvcyBhdXRvcmFpcwpwYXRyaW1vbmlhaXMgbsOjbyBjb21lcmNpYWlzIGRlIHV0aWxpemHDp8OjbyBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG8gaW5jbHVpLCBleGVtcGxpZmljYXRpdmFtZW50ZSwKb3MgZGlyZWl0b3MgZGUgZGlzcG9uaWJpbGl6YcOnw6NvIGUgY29tdW5pY2HDp8OjbyBww7pibGljYSBkYSBPQlJBLCBlbSBxdWFscXVlciBtZWlvIG91IHZlw61jdWxvLAppbmNsdXNpdmUgZW0gUmVwb3NpdMOzcmlvcyBEaWdpdGFpcywgYmVtIGNvbW8gb3MgZGlyZWl0b3MgZGUgcmVwcm9kdcOnw6NvLCBleGliacOnw6NvLCBleGVjdcOnw6NvLApkZWNsYW1hw6fDo28sIHJlY2l0YcOnw6NvLCBleHBvc2nDp8OjbywgYXJxdWl2YW1lbnRvLCBpbmNsdXPDo28gZW0gYmFuY28gZGUgZGFkb3MsIHByZXNlcnZhw6fDo28sIGRpZnVzw6NvLApkaXN0cmlidWnDp8OjbywgZGl2dWxnYcOnw6NvLCBlbXByw6lzdGltbywgdHJhZHXDp8OjbywgZHVibGFnZW0sIGxlZ2VuZGFnZW0sIGluY2x1c8OjbyBlbSBub3ZhcyBvYnJhcyBvdQpjb2xldMOibmVhcywgcmV1dGlsaXphw6fDo28sIGVkacOnw6NvLCBwcm9kdcOnw6NvIGRlIG1hdGVyaWFsIGRpZMOhdGljbyBlIGN1cnNvcyBvdSBxdWFscXVlciBmb3JtYSBkZQp1dGlsaXphw6fDo28gbsOjbyBjb21lcmNpYWw7CgooMykgUkVDT05IRUNFIHF1ZSBhIGNlc3PDo28gYXF1aSBlc3BlY2lmaWNhZGEgY29uY2VkZSDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPCkNSVVogbyBkaXJlaXRvIGRlIGF1dG9yaXphciBxdWFscXVlciBwZXNzb2Eg4oCTIGbDrXNpY2Egb3UganVyw61kaWNhLCBww7pibGljYSBvdSBwcml2YWRhLCBuYWNpb25hbCBvdQplc3RyYW5nZWlyYSDigJMgYSBhY2Vzc2FyIGUgdXRpbGl6YXIgYW1wbGFtZW50ZSBhIE9CUkEsIHNlbSBleGNsdXNpdmlkYWRlLCBwYXJhIHF1YWlzcXVlcgpmaW5hbGlkYWRlcyBuw6NvIGNvbWVyY2lhaXM7CgooNCkgREVDTEFSQSBxdWUgYSBvYnJhIMOpIGNyaWHDp8OjbyBvcmlnaW5hbCBlIHF1ZSDDqSBvIHRpdHVsYXIgZG9zIGRpcmVpdG9zIGFxdWkgY2VkaWRvcyBlIGF1dG9yaXphZG9zLApyZXNwb25zYWJpbGl6YW5kby1zZSBpbnRlZ3JhbG1lbnRlIHBlbG8gY29udGXDumRvIGUgb3V0cm9zIGVsZW1lbnRvcyBxdWUgZmF6ZW0gcGFydGUgZGEgT0JSQSwKaW5jbHVzaXZlIG9zIGRpcmVpdG9zIGRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIG9icmlnYW5kby1zZSBhIGluZGVuaXphciB0ZXJjZWlyb3MgcG9yCmRhbm9zLCBiZW0gY29tbyBpbmRlbml6YXIgZSByZXNzYXJjaXIgYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogZGUKZXZlbnR1YWlzIGRlc3Blc2FzIHF1ZSB2aWVyZW0gYSBzdXBvcnRhciwgZW0gcmF6w6NvIGRlIHF1YWxxdWVyIG9mZW5zYSBhIGRpcmVpdG9zIGF1dG9yYWlzIG91CmRpcmVpdG9zIGRlIHZveiBvdSBpbWFnZW0sIHByaW5jaXBhbG1lbnRlIG5vIHF1ZSBkaXogcmVzcGVpdG8gYSBwbMOhZ2lvIGUgdmlvbGHDp8O1ZXMgZGUgZGlyZWl0b3M7CgooNSkgQUZJUk1BIHF1ZSBjb25oZWNlIGEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTwpPU1dBTERPIENSVVogZSBhcyBkaXJldHJpemVzIHBhcmEgbyBmdW5jaW9uYW1lbnRvIGRvIHJlcG9zaXTDs3JpbyBpbnN0aXR1Y2lvbmFsIEFSQ0EuCgpBIFBvbMOtdGljYSBJbnN0aXR1Y2lvbmFsIGRlIEFjZXNzbyBBYmVydG8gZGEgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaIHJlc2VydmEKZXhjbHVzaXZhbWVudGUgYW8gQVVUT1Igb3MgZGlyZWl0b3MgbW9yYWlzIGUgb3MgdXNvcyBjb21lcmNpYWlzIHNvYnJlIGFzIG9icmFzIGRlIHN1YSBhdXRvcmlhCmUvb3UgdGl0dWxhcmlkYWRlLCBzZW5kbyBvcyB0ZXJjZWlyb3MgdXN1w6FyaW9zIHJlc3BvbnPDoXZlaXMgcGVsYSBhdHJpYnVpw6fDo28gZGUgYXV0b3JpYSBlIG1hbnV0ZW7Dp8OjbwpkYSBpbnRlZ3JpZGFkZSBkYSBPQlJBIGVtIHF1YWxxdWVyIHV0aWxpemHDp8Ojby4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVoKcmVzcGVpdGEgb3MgY29udHJhdG9zIGUgYWNvcmRvcyBwcmVleGlzdGVudGVzIGRvcyBBdXRvcmVzIGNvbSB0ZXJjZWlyb3MsIGNhYmVuZG8gYW9zIEF1dG9yZXMKaW5mb3JtYXIgw6AgSW5zdGl0dWnDp8OjbyBhcyBjb25kacOnw7VlcyBlIG91dHJhcyByZXN0cmnDp8O1ZXMgaW1wb3N0YXMgcG9yIGVzdGVzIGluc3RydW1lbnRvcy4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352018-10-12T05:01:24Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings
title C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings
spellingShingle C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings
Tenforde, Mark W.
C-Reactive Protein (CRP)
Tuberculosis
Interferon GammaInducible Protein 10 (IP-10)
Lipopolysaccharide (LPS)
Antiretroviral Therapy
title_short C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings
title_full C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings
title_fullStr C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings
title_full_unstemmed C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings
title_sort C-reactive protein (CRP), interferon gamma-inducible protein 10 (IP-10), and lipopolysaccharide (LPS) are associated with risk of tuberculosis after initiation of antiretroviral therapy in resource-limited settings
author Tenforde, Mark W.
author_facet Tenforde, Mark W.
Gupte, Nikhil
Dowdy, David W.
Asmuth, David M.
Balagopal, Ashwin
Pollard, Richard B.
Sugandhavesa, Patcharaphan
Lama, Javier R.
Pillay, Sandy
Cardoso, Sandra W.
Pawar, Jyoti
Santos, Breno
Riviere, Cynthia
Mwelase, Noluthando
Kanyama, Cecilia
Kumwenda, Johnstone
Hakim, James G.
Kumarasamy, Nagalingeswaran
Bollinger, Robert
Semba, Richard D.
Campbell, Thomas B.
Gupta, Amita
ACTG PEARLS
NWCS 319 Study Group
author_role author
author2 Gupte, Nikhil
Dowdy, David W.
Asmuth, David M.
Balagopal, Ashwin
Pollard, Richard B.
Sugandhavesa, Patcharaphan
Lama, Javier R.
Pillay, Sandy
Cardoso, Sandra W.
Pawar, Jyoti
Santos, Breno
Riviere, Cynthia
Mwelase, Noluthando
Kanyama, Cecilia
Kumwenda, Johnstone
Hakim, James G.
Kumarasamy, Nagalingeswaran
Bollinger, Robert
Semba, Richard D.
Campbell, Thomas B.
Gupta, Amita
ACTG PEARLS
NWCS 319 Study Group
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Tenforde, Mark W.
Gupte, Nikhil
Dowdy, David W.
Asmuth, David M.
Balagopal, Ashwin
Pollard, Richard B.
Sugandhavesa, Patcharaphan
Lama, Javier R.
Pillay, Sandy
Cardoso, Sandra W.
Pawar, Jyoti
Santos, Breno
Riviere, Cynthia
Mwelase, Noluthando
Kanyama, Cecilia
Kumwenda, Johnstone
Hakim, James G.
Kumarasamy, Nagalingeswaran
Bollinger, Robert
Semba, Richard D.
Campbell, Thomas B.
Gupta, Amita
ACTG PEARLS
NWCS 319 Study Group
dc.subject.en.pt_BR.fl_str_mv C-Reactive Protein (CRP)
Tuberculosis
Interferon GammaInducible Protein 10 (IP-10)
Lipopolysaccharide (LPS)
Antiretroviral Therapy
topic C-Reactive Protein (CRP)
Tuberculosis
Interferon GammaInducible Protein 10 (IP-10)
Lipopolysaccharide (LPS)
Antiretroviral Therapy
description Johns Hopkins University School of Medicine. Baltimore, Maryland, United States of America.
publishDate 2015
dc.date.issued.fl_str_mv 2015
dc.date.accessioned.fl_str_mv 2018-10-11T18:58:30Z
dc.date.available.fl_str_mv 2018-10-11T18:58:30Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv TENFORDE, Mark W. et al. C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings. PLoS ONE, v. 10, n. 2, p. 1-16, 2015.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/29551
dc.identifier.issn.pt_BR.fl_str_mv 1932-6203
dc.identifier.doi.none.fl_str_mv 10.1371/journal.pone.0117424
identifier_str_mv TENFORDE, Mark W. et al. C-Reactive Protein (CRP), Interferon Gamma-Inducible Protein 10 (IP-10), and Lipopolysaccharide (LPS) Are Associated with Risk of Tuberculosis after Initiation of Antiretroviral Therapy in Resource-Limited Settings. PLoS ONE, v. 10, n. 2, p. 1-16, 2015.
1932-6203
10.1371/journal.pone.0117424
url https://www.arca.fiocruz.br/handle/icict/29551
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/29551/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/29551/2/C-reactive%20protein%20%28CRP%29%2c%20interferon%20gamma-inducible%20protein_Sandra_Cardoso_etal_INI_Lapclin-AIDS_2015.pdf
https://www.arca.fiocruz.br/bitstream/icict/29551/3/C-reactive%20protein%20%28CRP%29%2c%20interferon%20gamma-inducible%20protein_Sandra_Cardoso_etal_INI_Lapclin-AIDS_2015.pdf.txt
bitstream.checksum.fl_str_mv 586c046dcfeef936e32f0323bb9a47c0
98ebd3421497c5f0195cbe08318816db
c500059aa74417573684970472a9fb81
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324988006105088